| Nov 7 |
Verastem GAAP EPS of -$0.60 beats by $0.14
|
| Nov 6 |
Verastem: Q3 Earnings Snapshot
|
| Nov 6 |
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
|
| Nov 1 |
Verastem Oncology submits NDA for ovarian cancer treatment
|
| Nov 1 |
Verastem Oncology completes rolling NDA submission to FDA for ovarian cancer treatment
|
| Oct 31 |
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
|
| Oct 31 |
Verastem Oncology to Participate in Upcoming Investor Conferences
|
| Oct 17 |
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
|
| Oct 9 |
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting
|
| Oct 7 |
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
